ATCC and Synthego have entered a strategic alliance to create customized cell models by combining high-quality CRISPR gene-editing services from Synthego with gold-standard, authenticated cell lines from ATCC.
Synthego’s CRISPR platforms leverage an integrated approach to genome editing that combines machine learning, automation, and extensive expertise to deliver high-quality, consistent results at an unprecedented scale. The combination of ATCC's broad selection of high-quality cells and Synthego's Engineered Cells allows researchers to confidently generate assay results and increase their speed to critical data with genome-edited cells in as little as 3 weeks.
What is CRISPR gene editing?
CRISPR is a powerful gene-editing technology that enables scientists to make complex gene edits such as engineered point mutations and gene fusions with more precision, efficiency, and flexibility than ever before. This technology uses a nuclease protein that carries with it an interchangeable short RNA molecule known as guide RNA. The guide RNA directs the nuclease protein to the gene of interest then the nuclease protein cuts the DNA. The cell then tries to repair that damage; during that repair process, the gene sequence at that location can be changed.
Learn more about CRISPRTake your research to the next level
Below is a selection of cell lines that are currently available for CRISPR gene editing through our partnership with Synthego. To customize these cell lines for your research, visit the Synthego website using the link below and let us know how we can take your research to the next level.
Take me to Synthego's website to customize my cell line
ATCC cell lines currently available for CRISPR editing through Synthego
ATCC Number | Product Name | Organism | Tissue | Disease | Cell Type |
---|---|---|---|---|---|
HTB-96 | U-2 OS | Human | Bone | Osteosarcoma | |
CCL-243 | K-562 | Human | Bone; marrow | Chronic myelogenous leukemia | |
CRL-2003 | TF-1 | Human | Bone; marrow | Erythroleukemia | Erythroblast |
CRL-9068 | NCI-H929 | Human | Bone; marrow | Plasmacytoma | B lymphocyte |
CRL-3304 | HMC3 | Human | Brain | Microglial cell | |
HTB-14 | U-87 MG | Human | Brain | Likely glioblastoma | |
CRL-10317 | MCF 10A | Human | Breast; mammary gland | Fibrocystic disease | Epithelial cell |
HTB-133 | T-47D | Human | Breast; mammary gland | Carcinoma; ductal | Epithelial cell |
HTB-22 | MCF7 | Human | Breast; mammary gland | Adenocarcinoma | Epithelial cell |
CCL-121 | HT-1080 | Human | Connective tissue | Fibrosarcoma | |
CRL-2190 | HK-2 | Human | Kidney; cortex; proximal tubule | Papilloma | |
CRL-1573 | 293 [HEK-293] | Human | Kidney; embryo | ||
CRL-3216 | 293T | Human | Kidney; embryo | ||
CCL-247 | HCT 116 | Human | Large intestine; colon | Carcinoma; colorectal | |
CCL-248 | T84 | Human | Large intestine; colon | Carcinoma; colorectal | |
HB-8064 | Hep3B2.1-7 | Human | Liver | Carcinoma; hepatocellular | |
HB-8065 | Hep G2 | Human | Liver | Carcinoma; hepatocellular | |
CCL-185 | A549 | Human | Lung | Carcinoma | Epithelial cell |
CRM-HTB-174 | NCI-H440 | Human | Lung | Papillary adenocarcinoma | Epithelial cell |
CRL-5807 | NCI-H358 | Human | Lung; bronchiole | Bronchioalveolar carcinoma, Non small cell lung cancer | |
HTB-161 | NIH:OVCAR-3 [OVCAR3] | Human | Ovary | Adenocarcinoma | Epithelial cell |
CRL-1420 | MIA PaCa-2 | Human | Pancreas | Carcinoma | Epithelial cell |
CRL-1682 | AsPC-1 | Human | Pancreas | Adenocarcinoma | |
CRL-1687 | BxPC-3 | Human | Pancreas | Adenocarcinoma | |
CRL-1469 | PANC-1 | Human | Pancreas; duct | Epithelioid carcinoma | |
CCL-155 | RPMI 8226 | Human | Peripheral blood | Plasmacytoma | B lymphocyte |
CCL-240 | HL-60 | Human | Peripheral blood | Acute promyelocytic leukemia | Promyeloblast |
TIB-152 | Jurkat, Clone E6-1 | Human | Peripheral blood | Acute T cell leukemia | T lymphoblast |
TIB-202 | THP-1 | Human | Peripheral blood | Acute monocytic leukemia | Monocyte |
CRL-1593.2 | U-937 | Human | Pleural effusion | Histiocytic lymphoma | |
CRL-1435 | PC-3 | Human | Prostate | Adenocarcinoma; grade IV | |
CRL-2505 | 22Rv1 | Human | Prostate | Carcinoma | Epithelial cell |
HTB-81 | DU 145 | Human | Prostate | Carcinoma | |
CRL-1619 | A375 | Human | Skin | Malignant melanoma | |
CCL-2 | HeLa | Human | Uterus; cervix | Adenocarcinoma | Epithelial cell |
CCL-86 | Raji | Human | Burkitts lymphoma | B lymphocyte | |
TIB-71 | RAW 264.7 | Mouse | Ascites | Abelson murine leukemia virus-induced tumor | Macrophage |
CCL-131 | Neuro-2a | Mouse | Brain | Neuroblastoma | Neuroblast |
CRL-2755 | EMT6 | Mouse | Breast | Carcinoma; mammary | Epithelial cell |
CRL-2539 | 4T1 | Mouse | Breast; mammary gland | Mimics human breast cancer; stage IV | |
CL-173 | 3T3-L1 | Mouse | Embryo | Fibroblast | |
CRL-1658 | NIH/3T3 | Mouse | Embryo | Fibroblast | |
CRL-2638 | CT26.WT | Mouse | Large intestine; colon | Carcinoma | Fibroblast |
CRL-1642 | LL/2 (LLC1) | Mouse | Lung | Lewis lung carcinoma | |
CRL-1772 | C2C12 | Mouse | Muscle | Myoblast | |
CRL-6475 | B16-F10 | Mouse | Skin | Melanoma | |
CRL-1446 | H9c2(2-1) | Rat | Heart; myocardium | Myoblast |